Advent Life Sciences

Advent Life Sciences is a leading transatlantic venture capital firm that focuses on investing in early and mid-stage life sciences companies. The firm emphasizes innovation in areas such as new drug discovery, medical technology, enabling technologies, and vaccines. Advent Life Sciences takes a hands-on approach, working closely with management teams to bring their visions to life, aiming for superior financial returns by bringing innovative solutions to patients. Advent Life Sciences has a strong portfolio of companies that have brought significant advancements in healthcare. Notable investments include AviadoBio, which focuses on gene therapy for neurodegenerative disorders, and Amphista Therapeutics, which develops protein degradation technologies for targeted cancer therapies. The firm also backs companies like Cellnovo, which created a micro insulin pump with connectivity, and Centessa Pharmaceuticals, a novel asset-centric pharmaceutical company. The firm is known for its experienced team of professionals, combining deep technical, commercial, and financial expertise. Key team members include Don Drakeman, Majid Kazmi, and Katrine Bosley, who bring substantial industry knowledge and strategic guidance to their portfolio companies. Advent Life Sciences is committed to supporting the growth of life sciences innovations, helping companies navigate the complex journey from scientific discovery to market-ready products.